08:34 AM EST, 03/05/2024 (MT Newswires) -- Dyne Therapeutics ( DYN ) reported a Q4 net loss of $1.09 per diluted share, wider than its loss of $0.74 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.93 per share.

The company reported no Q4 revenue, matching analyst expectations.

The biopharmaceutical company reported it had $123.1 million in cash, cash equivalents, and marketable securities as of Dec. 31, sufficient to fund operations through 2025.

Dyne Therapeutics' ( DYN ) shares were down more than 1% in recent Tuesday premarket activity.

Price: 27.31, Change: -0.4, Percent Change: -1.44